ALKS
Alkermes Plc
NASDAQ: ALKS · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$50.03
+3.50% today
Updated 2026-07-30
Market cap
$8.62B
P/E ratio
58.77
P/S ratio
5.52x
EPS (TTM)
$0.88
Dividend yield
—
52W range
$25 – $56
Volume
2.3M
WallStSmart proprietary scores
41
out of 100
Grade: D
Sell
Investment rating
5.3
Growth
C+7.0
Quality
B+5.0
Profitability
C+5.3
Valuation
C+4/9
Piotroski F-Score
Moderate
2.8
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$52.65
+5.24%
12-Month target
$28.21
-43.61%
Intrinsic (DCF)
$72.61
Margin of safety
+51.92%
3 Strong Buy11 Buy2 Hold0 Sell1 Strong Sell
Price chart
Stock snapshot
Strengths
+ Revenue growth 28.20% QoQ
+ 51.92% below intrinsic value
Risks
- Negative free cash flow $-169.83M
- P/E 58.77x — expensive valuation
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $1.11B | $1.66B | $1.56B | $1.48B | $1.56B |
| Net income | $-158.27M | $355.76M | $367.07M | $241.66M | $-66.48M |
| EPS | — | — | — | — | $0.88 |
| Free cash flow | $-17.21M | $353.31M | $405.64M | $480.33M | $-169.83M |
| Profit margin | -14.24% | 21.39% | 23.57% | 16.37% | 9.77% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-07-06 | GAFFIN, DAVID JOSEPH | Sale | 2,034 | $54.03 |
| 2026-07-01 | HOPKINSON, CRAIG C. | Sale | 8,300 | $51.46 |
| 2026-07-01 | HOPKINSON, CRAIG C. | Buy | 5,000 | $19.34 |
Peer comparison
Smart narrative
Alkermes Plc trades at $50.03. representing a P/E of 58.77x trailing earnings. Our Smart Value Score of 41/100 indicates the stock is fair. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 2.77, it sits in the grey zone. TTM revenue stands at $1.56B. with profit margins at 9.77%. Our DCF model estimates intrinsic value at $72.61.
Frequently asked questions
What is Alkermes Plc's stock price?
Alkermes Plc (ALKS) trades at $50.03, on a P/E of 58.8x and a P/S of 5.5x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Alkermes Plc overvalued?
Alkermes Plc carries a Smart Value Score of 41/100 (Grade D), which we rate Sell. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $72.61 versus the $50.03 price, a 51.9% margin of safety on a cash flow basis.
What is the price target of Alkermes Plc (ALKS)?
The 12-month analyst consensus target is $52.65, about 5.2% above the current $50.03. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the intrinsic value of Alkermes Plc (ALKS)?
Our DCF model estimates intrinsic value at $72.61, a +51.9% margin of safety versus today's $50.03. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is Alkermes Plc's revenue?
Alkermes Plc's trailing twelve-month revenue is $1.56B. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Alkermes Plc's Altman Z-Score is 2.77, which places it in the grey zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio5.52x
ROE8.72%
Beta0.29
50D MA$44.82
200D MA$34.49
Shares out0.17B
Float0.15B
Short ratio—
Avg volume2.3M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—